 |
| Global Idiopathic Hypersomnia Treatment Market Size |
Idiopathic hypersomnia is a chronic neurological sleep disorder characterized
by excessive daytime sleepiness that is not caused by other medical conditions
or inadequate sleep. Treatments for idiopathic hypersomnia help reduce
excessive daytime sleepiness and improve overall quality of life. Sodium
oxybate, pitolisant, central nervous system stimulants and wakefulness
promoting agents are commonly used to treat symptoms associated with idiopathic
hypersomnia. Modafinil and armodafinil are the most widely prescribed
medications to reduce daytime sleepiness.
The global
Idiopathic Hypersomnia Treatment Market is estimated to be valued at US$ 338.42 Mn in 2023 and is expected
to exhibit a CAGR of 8.7% over the
forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Market key trends:
Increasing awareness and diagnosis rates of idiopathic hypersomnia are expected
to drive the market growth over the forecast period. Growing acceptance of the
Center for Sleep Medicine guidelines is helping standardize diagnosis. In
addition, improving access to sleep specialists and polysomnography tests in
developed regions is contributing to more accurate identification of patients.
Research is also ongoing to develop new treatment alternatives which can
address unmet needs. This includes medications possessing lower risks of side
effects and abuse potential compared to existing therapies. Such efforts are
anticipated to expand treatment options and further supplement market expansion.
Segment
Analysis:
The global idiopathic hypersomnia treatment market is dominated by the
narcolepsy drugs segment. These drugs help treat excessive daytime sleepiness
and cataplexy associated with idiopathic hypersomnia. Sodium oxybate (Xyrem)
from Jazz Pharmaceuticals holds a major share owing to its strong efficacy and
safety profile. In addition, wakefulness promoting agents (modafinil and
armodafinil) from companies like Teva and Amneal are also commonly used as
off-label treatments. Researchers are also exploring the efficacy of other drug
classes like antidepressants and therapy approaches like light therapy to
improve symptoms.
Key Takeaways:
The Global
Idiopathic Hypersomnia Treatment Market Size is estimated to be valued
at US$ 338.42 Mn in 2023 and is
expected to exhibit a CAGR of 8.7% over
the forecast period 2023 to 2030.
North America accounts for a significant share of the global idiopathic
hypersomnia treatment market currently due to high awareness about the
condition and availability of effective therapies. However, Asia Pacific is
expected to witness rapid growth over the forecast period supported by
improving healthcare infrastructure and rising diagnosis rates in countries
like China and India.
Key players operating in the idiopathic hypersomnia treatment market are Takeda
Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Jazz
Pharmaceuticals, Inc., BIOPROJET, Avadel Pharmaceuticals, Plc. GlaxoSmithKline
plc, Pfizer Inc., Theranexus, Fisher & Paykel Healthcare Limited, Drive
DeVilbiss Healthcare LLC, and Merck & Co. Inc. Jazz Pharmaceuticals
dominates with its narcolepsy drug Xyrem that is also effective for idiopathic
hypersomnia. Other players are focusing on developing newer treatment options
including more selective modulators and digital therapies.
Discover More@ https://www.pressreleasebulletin.com/idiopathic-hypersomnia-treatment-market-scope/